×
About 2,133 results

ALLMedicine™ Hemochromatosis Center

Research & Reviews  733 results

Genetic modifiers of penetrance to liver endpoints in HFE hemochromatosis: associations...
https://doi.org/10.1002/hep.32575
Hepatology (Baltimore, Md.); Pilling LC, Atkins JL et. al.

May 15th, 2022 - The iron overload condition Hereditary Heamochromatosis (HH) can cause liver cirrhosis and cancer, diabetes and arthritis. Male HFE p.C282Y homozygotes have greatest risk, yet only a minority develop these conditions. We aimed to determine whether...

Evaluation of Patients With Liver Disease
https://clinicaltrials.gov/ct2/show/NCT00001971

May 13th, 2022 - This is a general clinical research protocol to allow for evaluation, investigation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to study the natural history and pathogenesis of various l...

Rhabdomyolysis in Young Adult Male Stabilized on Mirtazapine and with History of COVID-...
https://doi.org/10.1017/S1092852922000347
CNS Spectrums; Philippe C, Misquitta D et. al.

Apr 29th, 2022 - The purpose of this case study is to review the clinical presentation and medical workup of a young adult male presenting with rhabdomyolysis in the setting of suspected contributing factors, including treatment with mirtazapine and history of COV...

Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III ...
https://doi.org/10.1002/ajh.26581
American Journal of Hematology; van Vuren A, Kerkhoffs JL et. al.

Apr 27th, 2022 - Iron overload is a severe general complication of hereditary anemias. Treatment with iron chelators is hampered by important side-effects, high costs, and the lack of availability in many countries with a high prevalence of hereditary anemias. In ...

An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
https://clinicaltrials.gov/ct2/show/NCT05335603

Apr 19th, 2022 - Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death. The condition is associated with several other chronic liver diseases like autoimmune hepatit...

see more →

Guidelines  5 results

ACG Clinical Guideline: Hereditary Hemochromatosis.
https://doi.org/10.14309/ajg.0000000000000315
The American Journal of Gastroenterology; Kowdley KV, Brown KE et. al.

Jul 25th, 2019 - Hereditary hemochromatosis (HH) is one of the most common genetic disorders among persons of northern European descent. There have been recent advances in the diagnosis, management, and treatment of HH. The availability of molecular diagnostic tes...

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.

Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...

EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929861
European Journal of Human Genetics : EJHG; Porto G, Brissot P et. al.

Jul 15th, 2015 - Molecular genetic testing for hereditary hemochromatosis (HH) is recognized as a reference test to confirm the diagnosis of suspected HH or to predict its risk. The vast majority (typically >90%) of patients with clinically characterized HH are ho...

Diagnosis and management of hemochromatosis: 2011 practice guideline by the American As...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149125
Hepatology (Baltimore, Md.); Bacon BR, Adams PC et. al.

Apr 1st, 2011 - Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases.|2011|Bacon BR,Adams PC,Kowdley KV,Powell LW,Tavill AS,|blood,diagnosis,physiopathology,therapy,metabolism,pathology,m...

EASL clinical practice guidelines for HFE hemochromatosis.
https://doi.org/10.1016/j.jhep.2010.03.001
Journal of Hepatology;

May 18th, 2010 - Iron overload in humans is associated with a variety of genetic and acquired conditions. Of these, HFE hemochromatosis (HFE-HC) is by far the most frequent and most well-defined inherited cause when considering epidemiological aspects and risks fo...

see more →

Drugs  15 results see all →

Clinicaltrials.gov  24 results

Evaluation of Patients With Liver Disease
https://clinicaltrials.gov/ct2/show/NCT00001971

May 13th, 2022 - This is a general clinical research protocol to allow for evaluation, investigation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to study the natural history and pathogenesis of various l...

An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
https://clinicaltrials.gov/ct2/show/NCT05335603

Apr 19th, 2022 - Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death. The condition is associated with several other chronic liver diseases like autoimmune hepatit...

Effect of Taking a Single Tablet of Iron on Insulin Secretion
https://clinicaltrials.gov/ct2/show/NCT05238987

Mar 2nd, 2022 - Oral iron supplementation is the treatment of choice in patients with iron deficiency anemia. In several developing countries, including India, iron is routinely supplemented to pregnant women, especially during the second and third trimesters of ...

A Two-year Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis.
https://clinicaltrials.gov/ct2/show/NCT03203850

Dec 6th, 2021 - The purpose of this study is to evaluate the efficacy and safety of deferasirox film coated tablet (FCT) versus phlebotomy for the management of iron overload in adults with HH at risk of iron-related morbidity. This evaluation will provide inform...

Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis
https://clinicaltrials.gov/ct2/show/NCT01810965

Jun 11th, 2021 - Hemochromatosis type 1 is one of the most frequent genetic disease since the genetic predisposition (homozygosity for the C282Y mutation of the HFE gene) is encountered in about 3/1000 white subjects (5/1000 in Brittany, France). For the half of t...

see more →

News  61 results

Dr. Fitzgerald on Minimizing Use of Chemotherapy in Breast Cancer
https://www.onclive.com/view/dr-fitzgerald-on-minimizing-use-of-chemotherapy-in-breast-cancer

Oct 6th, 2021 - Dennis Fitzgerald, MD, a specialist in breast cancer, lung cancer, non-Hodgkin lymphoma and hemochromatosis, Hackensack Meridian Health Riverview Medical Center, discusses the pivotal TAILORx trial, which found that for intermediate-risk women wit...

Pediatric NAFLD almost always stems from excess body weight, not other etiologies
https://www.mdedge.com/pediatrics/article/238291/obesity/pediatric-nafld-almost-always-stems-excess-body-weight-not-other
Will Pass

Apr 7th, 2021 - Nonalcoholic fatty liver disease (NAFLD) in children is almost always caused by excess body weight, not other etiologies, based on a retrospective analysis of 900 patients. Just 2% of children with overweight or obesity and suspected NAFLD had oth.

Iron Chelation Therapy Efficacy and Safety in MDS
https://www.onclive.com/view/iron-chelation-therapy-efficacy-and-safety-in-mds

Apr 2nd, 2021 - Transcript:James M. Foran, MD, FRCPC: What is the role of the patient in deciding on iron chelation therapy? There are two oral chelating agents—a third one that’s approved in a different setting, deferiprone—and then there’s Desferal, or de...

Negative Effects Associated with Iron Overload
https://www.onclive.com/view/negative-effects-associated-with-iron-overload

Apr 2nd, 2021 - Transcript:David P. Steensma, MD: In patients with congenital anemias, like severe beta thalassemia, it’s clear that iron is a major contributor to morbidity and mortality. If you don’t adequately chelate patients with severe transfusion-defendant...

Diagnosis of HCC: Presentation of Disease
https://www.onclive.com/view/diagnosis-of-hcc-presentation-of-disease

Apr 2nd, 2021 - Transcript: Ghassan K. Abou-Alfa, MD: Hello, and welcome to this OncLive® Peer Exchange® panel discussion titled Global Perspective on Treatment of Hepatocellular Carcinoma. The treatment of advanced hepatocellular carcinoma is complicated by ...

see more →

Patient Education  15 results see all →